Functional ProvidersNetwork, LLC
Building the infrastructure for provider-powered precision medicine.
FPN is building the network, services, tools, and infrastructure required to make root-cause, cash-pay precision medicine scalable and accessible.
It serves functional and integrative providers who want to deliver individualized care but need better systems for turning complex patient data into clear insights, patient education, provider-reviewed treatment plans, and practical next steps.
A simple model for scaling precision medicine.
Genetics creates the signal. A provider-controlled platform turns it into action. A network scales it. Each layer reinforces the next.
Genetic testing creates the personalization signal — a powerful, individualized starting point for root-cause care.
PeakHealth247 turns that signal into provider-reviewable action — reports, education, and editable treatment plans.
FPN scales the model through provider networks, white-label partnerships, media assets, and strategic marketplace integrations.
FPN is not building a direct-to-consumer wellness brand or a standalone genetic testing company. It is building the operating layer for provider-powered precision medicine.
One parent company. A connected precision medicine ecosystem.
FPN is the parent behind a growing ecosystem: two wholly owned subsidiaries and a proprietary technology platform that together connect testing, education, provider authority, treatment-plan development, and commercial activation.
The network, services, tools, and infrastructure for provider-powered precision medicine. FPN wholly owns the operating businesses below and owns and operates the PeakHealth247 platform.
FPN's genetic testing services company — provider-focused nutrigenomic testing, reporting, interpretation support, and workflow infrastructure for functional and integrative care.
FPN's white-label media and distribution asset through Sinclair Broadcasting — supporting patient education, provider visibility, market awareness, and scalable communication.
FPN's proprietary technology platform for transforming genetic, symptom, and diagnostic data into provider-reviewable, patient-friendly, actionable insight.
The genetic testing wedge.
DNA Regimen is FPN's current commercial engine and primary entry point into the functional and integrative provider market — a provider-focused nutrigenomic test that reveals the genetic factors shaping each patient's wellness.
Clinically relevant SNPs analyzed across nine key health categories — informing nutritional needs, metabolic tendencies, and functional health patterns.
The wedge, not the whole. The larger value is the workflow surrounding the test — onboarding, data collection, interpretation, patient education, provider review, and integration into a broader care plan. FPN's opportunity is what happens after the result is generated.
From data to provider-reviewed action.
PeakHealth247 is FPN's proprietary platform for turning patient-specific data into practical, provider-controlled precision medicine workflows. It synthesizes the inputs — and generates everything a provider needs to review, edit, and release.
PeakHealth247 does not replace the provider — it gives the provider a scalable precision medicine workflow. Treatment-plan content is always routed to the provider for review before it reaches the patient, preserving provider authority and the patient relationship.
Provider-first and consumer-initiated.
FPN supports both routes into precision medicine — capturing demand from both sides of the market while keeping the provider at the center.
A functional or integrative provider offers DNA Regimen testing to a patient and uses PeakHealth247 to review findings, educate the patient, and approve treatment-plan content.
Where permitted by law, a consumer purchases testing directly. After results process, PeakHealth247 lets the patient invite a provider into the workflow to review, amend, approve, and release content.
The consumer may initiate the process, but the provider remains the trusted reviewer and decision-maker — so FPN can acquire demand from both sides without reducing precision medicine to an unsupervised DTC report.
Products inside the provider-controlled plan.
PeakHealth247 treatment plans go beyond educational summaries. They may include lifestyle guidance and provider-editable lists of recommended products — with direct links — subject always to provider review, judgment, applicable law, and scope of practice.
Most product marketplaces sit outside the treatment plan. PeakHealth247 places relevant products inside the provider-controlled care workflow — at the exact moment recommendations are being reviewed, approved, and acted upon.
From a testing wedge to a platform.
Nutrigenomics is today's commercial wedge. The long-term opportunity is to expand PeakHealth247 into a diagnostic synthesis and treatment-plan activation layer that incorporates many data sources.
DNA Regimen's provider-focused test is the commercial entry point and the personalization signal the platform is built around.
White-label genetics is the beachhead.
FPN is growing primarily through DNA Regimen white-label genetic testing agreements with organizations that already serve large provider networks — scaling through existing relationships rather than clinic-by-clinic acquisition.
White-label genetics is the beachhead. Provider-controlled precision medicine infrastructure is the expansion.
Intelligent personalization at the center of practitioner wellness.
Precision medicine is moving from specialty practice to standard of care. FPN sits at the center of three converging, fast-growing markets — building the infrastructure for what comes next.
Projected global precision medicine market by 2035, driven by demand for personalized, data-informed healthcare.
Projected precision genomic testing market by 2030 as providers increasingly use genetic data to guide care.
Projected global genetic testing market by 2030, growing at a 22.5% CAGR.
| Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|
| Revenue | $33.7M | $69.3M | $106.0M | $142.2M | $178.9M |
| Costs | $3.6M | $5.3M | $6.0M | $6.7M | $7.8M |
| EBITDA | $30.0M | $64.1M | $100.0M | $135.5M | $171.1M |
| K1 distributions | $9.0M | $19.2M | $30.0M | $40.7M | $51.4M |
| Reinvestment | $21.1M | $45.0M | $70.1M | $95.0M | $119.9M |
| Implied multiple | 2.5× | 5.5× | 7.5× | 8.0× | 9.0× |
| Implied valuation | $75.5M | $353.1M | $751.2M | $1.10B | $1.50B |
Figures reflect management projections and are illustrative, not a guarantee of future performance.
Review the process & impact.
Supporting materials that show how genetic testing works in practice and the impact for providers.